GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akari Therapeutics PLC (NAS:AKTX) » Definitions » Cyclically Adjusted Book per Share

Akari Therapeutics (Akari Therapeutics) Cyclically Adjusted Book per Share : $40.81 (As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Akari Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Akari Therapeutics's adjusted book value per share for the three months ended in Mar. 2024 was $-0.445. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $40.81 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-05-26), Akari Therapeutics's current stock price is $1.95. Akari Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $40.81. Akari Therapeutics's Cyclically Adjusted PB Ratio of today is 0.05.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Akari Therapeutics was 0.46. The lowest was 0.00. And the median was 0.00.


Akari Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Akari Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akari Therapeutics Cyclically Adjusted Book per Share Chart

Akari Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 21.42

Akari Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 7.98 21.42 40.81

Competitive Comparison of Akari Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Akari Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akari Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akari Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Akari Therapeutics's Cyclically Adjusted PB Ratio falls into.



Akari Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Akari Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.445/131.7762*131.7762
=-0.445

Current CPI (Mar. 2024) = 131.7762.

Akari Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201312 289.110 98.326 387.465
201403 0.000 99.695 0.000
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 79.907 99.070 106.287
201503 93.278 99.621 123.386
201506 34.975 100.684 45.776
201509 70.189 100.392 92.132
201512 82.738 99.792 109.256
201603 78.726 100.470 103.256
201606 68.921 101.688 89.314
201609 69.695 101.861 90.163
201612 57.915 101.863 74.923
201703 38.033 102.862 48.724
201706 38.808 103.349 49.482
201709 22.148 104.136 28.027
201712 22.487 104.011 28.490
201803 21.399 105.290 26.782
201806 11.309 106.317 14.017
201809 7.975 106.507 9.867
201812 3.936 105.998 4.893
201903 1.539 107.251 1.891
201906 -1.662 108.070 -2.027
201909 3.094 108.329 3.764
201912 0.007 108.420 0.009
202003 1.264 108.902 1.530
202006 1.972 108.767 2.389
202009 2.869 109.815 3.443
202012 4.878 109.897 5.849
202103 2.047 111.754 2.414
202106 0.801 114.631 0.921
202109 4.775 115.734 5.437
202112 2.334 117.630 2.615
202203 4.695 121.301 5.100
202206 2.806 125.017 2.958
202212 0.481 125.222 0.506
202303 0.000 127.348 0.000
202306 0.549 128.729 0.562
202312 -0.035 129.419 -0.036
202403 -0.445 131.776 -0.445

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Akari Therapeutics  (NAS:AKTX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Akari Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1.95/40.81
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Akari Therapeutics was 0.46. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Akari Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Akari Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Akari Therapeutics (Akari Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
75/76 Wimpole Street, London, GBR, W1G 9RT
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. It operates mainly in United States and United Kingdom.
Executives
Donald Allen Williams director C/O PRYOR CASHMAN LLP, 7 TIMES SQUARE, NEW YORK NY 10036
David Byrne director C/O AKARI THERAPEUTICS, PLC, 24 WEST 40TH STREET, 8TH FLOOR, NEW YORK NY 10018
Robert M Shaw officer: General Counsel and Secretary C/O BIOTECHNOLOGY GENERAL CORP, ONE TOWER CENTER BLVD 14TH FLR, EAST BRUNSWICK NJ 08816
Clive Richardson director, officer: COO C/O LANDMARK FIDUCIAIRE (SUISSE) SA, 6 PLACE DES EAUX-VIVES, PO BOX 3461, GENEVA V8 1211
Rpc Pharma Ltd 10 percent owner C/O LANDMARK FIDUCIAIRE (SUISSE) SA, 6 PLACE DES EAUX-VIVES, PO BOX 3461, GENEVA V8 1211
Ray Prudo director, 10 percent owner C/O LANDMARK FIDUCIAIRE (SUISSE) SA, 6 PLACE DES EAUX-VIVES, PO BOX 3461, GENEVA V8 1211
Stuart Ungar director, 10 percent owner C/O LANDMARK FIDUCIAIRE (SUISSE) SA, 6 PLACE DES EAUX-VIVES, PO BOX 3461, GENEVA V8 1211
James Hill director, 10 percent owner C/O LANDMARK FIDUCIAIRE (SUISSE) SA, 6 PLACE DES EAUX-VIVES, PO BOX 3461, GENEVA V8 1211
Mark S Cohen director C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
Allan Shaw director C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
Dov Elefant officer: Chief Financial Officer EPICEPT CORPORATION, 270 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632
Gur Roshwalb director, officer: Chief Executive Officer C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
David Sidransky director JOHNS HOPKINS UNIVERSITY, 720 RUTLAND AVENUE, BALTIMORE MD 21205
Amos Eiran director C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
Lau Johnson Yiu Nam director

Akari Therapeutics (Akari Therapeutics) Headlines

From GuruFocus